were to refrain from changes to oral antidiabetic, lipid-lowering,and antihypertensive medications during the study, unless in-structed otherwise by the investigator. Use of concomitantweight-loss agents was not allowed; no supplementary lifestylemodification program was applied. A common clinical protocol was approved for each site by the appropriate institutional review board, and all patients providedwritten informed consent before participation. The study wasconducted in accordance with the principles described in theDeclaration of Helsinki (1946) up to and including the Seoulrevision (2008) (18). Study design This study was a randomized, comparator-controlled, open-